Roche announces positive Phase III study results for Tecentriq plus Cotellic and Zelboraf in people with previously untreated BRAF V600 mutation-positive advanced melanoma
Basel, 13 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma, met its primary endpoint of progression-free survival (PFS). The study showed adding Tecentriq ® (atezolizumab) to Cotellic® (cobimetinib) and Zelboraf® (vemurafenib) helped to reduce the risk of disease worsening or death, compared to placebo plus Cotellic and Zelboraf. A significant and clinically meaningful improvement in PFS was demonstrated in the study. The safety profile observed in IMspire150 was consistent with the known safety profiles of the individual medicines. Results from the study will be presented at an upcoming medical meeting and discussed with health authorities, including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA).“By combining a cancer immunotherapy with targeted therapies, we hope to offer a new approach that improves outcomes for people with advanced, BRAF-mutant melanoma. " said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. " We look forward to discussing the results with health authorities around the world. ” Roche has an extensive clinical trial development programme for Tecentriq, with more than 50 ongoing studies, including multiple Phase III studies across lung, kidney, skin, breast, colorecta...
Publication date: Available online 24 January 2020Source: Journal of Genetics and GenomicsAuthor(s): Qianru Huang, Xu Liu, Yujia Zhang, Jingyao Huang, Dan Li, Bin LiAbstractRegulatory T (Treg) cells, a subtype of CD4+ T cells with distinct immunosuppressive, are vital for maintaining immune homeostasis in healthy people. FOXP3 (Forkhead box protein P3), a member of the forkhead–winged-helix family, is the pivotal transcriptional factor of Treg. The expression, post-translational modifications and protein complex of FOXP3 present a great impact on the functional stability and immune plasticity of Treg in vivo. In part...
This article describes details of each stage of the mission and includes a discussion of key aspects of logistics and patient care posed by such evacuations. PMID: 31977424 [PubMed - in process]
PMID: 31977420 [PubMed - in process]
This article explores the factors that contribute to polypharmacy and discusses its negative physiological, psychological, and economic effects. It also describes strategies for reducing polypharmacy, including both "explicit" approaches, which are grounded in the findings of literature reviews and expert opinion, and "implicit" approaches, which are based on the provider's interpretation of clinical data and the patient's medication regimen. PMID: 31977416 [PubMed - in process]
This article describes key characteristics of nonpermanent contraceptive methods, including mechanism of action, correct use, failure rates with perfect and typical use, contraindications, benefits, side effects, discontinuation procedures, and innovations in the field. We also discuss how contraceptive care is related to nursing ethics and health inequities. PMID: 31977414 [PubMed - in process]
Authors: PMID: 31977403 [PubMed - in process]
ConclusionWe present the first risk score model to predict IGBC. The model estimates the expected risk for the individual patient and may help to optimize treatment strategies.
“Although the United States leads the world in health care spending, it fares far worse than its peers on coverage and most dimensions of value. Cost and coverage are intertwined. Many Americans cannot afford health insurance, and even those with insurance face substantial cost-related barriers to care. Employer-sponsored insurance is less prevalent and more expensive than in the past, and in response, deductibles have grown and benefits have been cut. The long-term solvency of U.S. public... ACP Endorses Single-Payer system
Authors: Zhang J, Si J, Gan L, Guo M, Yan J, Chen Y, Wang F, Xie Y, Wang Y, Zhang H Abstract Cervical cancer is the second most common malignant tumour threatening women's health. In recent years, heavy-ion beam therapy is becoming a newly emerging therapeutic mean of cancer; however, radio-resistance and radiation-induced damage constitute the main obstacles for curative treatment of cervical cancer. Therefore, to identify the radiosensitizers is essential. Here, we investigated the effects of Wnt signalling pathway on the response of 12C6+ radiation in HeLa cells. XAV939, an inhibitor of Wnt signalling pathway, w...
More News: Allergy & Immunology | Biotechnology | Bladder Cancer | Breast Cancer | Cancer | Cancer & Oncology | Clinical Trials | Colorectal Cancer | Dermatology | Diabetes | Endocrinology | European Medicines Agency (EMA) | Food and Drug Administration (FDA) | France Health | Head and Neck Cancer | Immunotherapy | Infectious Diseases | International Medicine & Public Health | Japan Health | Liver | Lung Cancer | Melanoma | Men | Opthalmology | Ovarian Cancer | Ovaries | Pharmaceuticals | Science | Skin | Skin Cancer | Study | Switzerland Health | Urology & Nephrology | USA Health | WHO